Biomarker or genomic testing analyses tumour cells at a molecular level, determining the type of abnormality present in the tumour, so that personalised therapeutic decisions can be made.  
Although two tumours of the same location look the same when viewed under a microscope, their genetic abnormality may be different, as a result they will not react to treatment in the same way.
 
Identifying these alterations opens up a range of new drugs aimed at these specific mutations.

Thanks to the information provided by genomic tests, we can:
 

• Design increasingly accurate treatment, targeted at a specific abnormality.

 

• Personalise treatment for each patient

 

• Offer less toxic treatment as it only affects tumour cells rather than normal cells,

 

• Improve effectiveness whilst having far fewer side effects

 

• Prolong patient survival and offer a better quality of life.

 

• FoundationOne®: test for characterisation of mutations and search for targeted therapeutic treatments for solid tumours in a tumour biopsy sample. It allows a search for targeted therapies for the abnormalities found.

 

• Foundation One Heme® test for characterisation of mutations and search for targeted therapeutic treatment for haematological malignancies, sarcomas and some paediatric tumours.

 

• Foundation ACT®: diagnostic genetic test ondiagnostic genetic test on blood samples (Liquid Biopsy) when no tumour tissue is available, mutation sequencing and therapeutic targets. It allows a search for targeted therapies using the abnormalities found in tumours without sufficient biological sample,. when no tumour tissue is available, mutation sequencing and therapeutic targets. It allows a search for targeted therapies using the abnormalities found in tumours without sufficient biological sample.

 

• MammaPrint®: mutation sequencing in early-stage breast cancer to safely determine risk of relapse and whether or not chemotherapy is needed.

 

• Oncotype DX®: mutation sequencing in early-stage breast cancer to safely determine the risk of relapse and whether or not chemotherapy is needed.

 

• Prosigna®: mutation sequencing in early-stage breast cancer to safely determine the risk of relapse and whether or not chemotherapy is needed.

 

• OncotypeDX Colon Recurrence Score®:test for mutation characterisation and search for therapeutic targets in solid tumours in a tumour biopsy sample. It allows the search for targeted therapies on the abnormalities found.

 

• ONCODEEP TM: test for mutation characterisation and search for therapeutic targets in solid tumours in a tumour biopsy sample. It allows the search for targeted therapies on the abnormalities found.

 

• GUARDANT 360: genomic blood tests (Liquid Biopsy).